ArticlePharmacogenetics and genomics2013
FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response.
Article in Pharmacogenetics and genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Etiology Model of Kawasaki Disease and Multisystem Inflammatory Syndromes: Mast Cell Activation.Current issues in molecular biology · 2026Article
- Pharmacogenomics of coronary artery response to intravenous gamma globulin in kawasaki disease.NPJ genomic medicine · 2024Article
- Article
- Pharmacogenomics of intravenous immunoglobulin response in Kawasaki disease.Frontiers in immunology · 2023Article
- TheFrontiers in genetics · 2022Article
- Identification of increased expression of activating Fc receptors and novel findings regarding distinct IgE and IgM receptors in Kawasaki disease.Pediatric research · 2021Article
- Epigenetics in Kawasaki Disease.Frontiers in pediatrics · 2021Review
- Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.Clinical rheumatology · 2020Article
- Identification of SAMD9L as a susceptibility locus for intravenous immunoglobulin resistance in Kawasaki disease by genome-wide association analysis.The pharmacogenomics journal · 2020Article
- Lower CMV and EBV Exposure in Children With Kawasaki Disease Suggests an Under-Challenged Immune System.Frontiers in pediatrics · 2020Article
- Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine.Frontiers in immunology · 2019Review
- Extensive Ethnic Variation and Linkage Disequilibrium at theFrontiers in immunology · 2019Article
- Leveraging Genetic Findings for Precision Medicine in Vasculitis.Frontiers in immunology · 2019Review
- One Size Does Not Fit All: Genetic Prediction of Kawasaki Disease Treatment Response in Diverse Populations.Circulation. Cardiovascular genetics · 2017Article
- Article
- Article
- Imputation of class I and II HLA loci using high-density SNPs from ImmunoChip and their associations with Kawasaki disease in family-based study.International journal of immunogenetics · 2015Article
- High-density genotyping of immune loci in Kawasaki disease and IVIG treatment response in European-American case-parent trio study.Genes and immunity · 2014Article
- Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies.Frontiers in immunology · 2014Review
- Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveKawasaki disease (KD), response to intravenous immunoglobulin (IVIG) therapy, and associated coronary artery disease progression have been associated with genetic polymorphisms in Fc gamma receptor (FcγR) genes. However, it is not known whether the existing gene copy number (GCN) variability relates to KD treatment response, susceptibility, or associated sequelae.
methodsThe copy number of individuals with KD (n=510) and their family members (n=808) for three variable FcγRs was assessed using pyrosequencing. We performed the transmission disequilibrium test to examine the association of GCN for FcγRs (FcγR2C, FcγR3A, and FcγR3B) with susceptibility and used logistic regression models to determine its association with IVIG treatment outcomes.
resultsFcγR2C and FcγR3B GCN were significantly associated with KD susceptibility. IVIG response was associated with GCN variations of FcγR3B in Whites and FcγR2C in Hispanics, and gene risk score based on single nucleotide polymorphism and GCN in FcγRs were significantly different between IVIG responders and nonresponders among Whites. We found no significant associations between coronary artery disease and any of the FcγR copy numbers.
conclusionGCN of FcγR2C and FcγR3B influences IVIG treatment response and predisposes individuals to KD, providing potential insights into understanding the mechanism of the FcγR gene family in the IVIG pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.